Piqray Improves Overall Survival for Adv. HR+, HER2- PIK3CA+

Options

Piqray Improves Overall Survival for Advanced-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer With PIK3CA Mutation
October 16, 2020

Postmenopausal women and men diagnosed with advanced-stage hormone-receptor-positive, HER2-negative breast cancer with a PIK3CA mutation lived about 8 months longer when treated with the combination of the targeted therapy Piqray and the hormonal therapy Faslodex compared to Faslodex alone. Read more...

Categories